Tuberculosis, Multidrug-Resistant
"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Descriptor ID |
D018088
|
| MeSH Number(s) |
C01.252.410.040.552.846.775
|
| Concept/Terms |
Tuberculosis, Multidrug-Resistant- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
|
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in this website by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 4 | 1 | 5 |
| 2012 | 4 | 2 | 6 |
| 2013 | 6 | 0 | 6 |
| 2014 | 1 | 1 | 2 |
| 2015 | 5 | 2 | 7 |
| 2016 | 2 | 1 | 3 |
| 2017 | 8 | 0 | 8 |
| 2018 | 20 | 1 | 21 |
| 2019 | 8 | 2 | 10 |
| 2020 | 11 | 1 | 12 |
| 2021 | 12 | 0 | 12 |
| 2022 | 9 | 0 | 9 |
| 2023 | 7 | 0 | 7 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles.
-
Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
-
Validation of a Handheld 6-Lead Device for QT Interval Monitoring in Resource-Limited Settings. JAMA Netw Open. 2024 Jun 03; 7(6):e2415576.
-
Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
-
Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrob Agents Chemother. 2024 May 02; 68(5):e0158323.
-
Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study. BMJ Open. 2023 11 17; 13(11):e067121.
-
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024 Feb; 12(2):117-128.
-
Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South Africa. S Afr Med J. 2023 Nov 06; 113(11):47-56.
-
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2023 09 18; 77(6):892-900.
-
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis. Lancet Infect Dis. 2023 07; 23(7):778-780.